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Matrix metalloproteinaseUrokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP9, gelatinase B) have
separately been recognized to play important roles in various tissue remodeling processes. In this study, we
demonstrate that deﬁciency for MMP9 in combination with ablation of either uPA- or tissue-type
plasminogen activator (tPA)-catalyzed plasminogen activation is critical to accomplish normal gestation in
mice. Gestation was also affected by simultaneous lack of MMP9 and the uPA receptor (uPAR). Interestingly,
uPA-deﬁciency additionally exacerbated the effect of MMP9-deﬁciency on bone growth and an additive effect
caused by combined lack in MMP9 and uPA was observed during healing of cutaneous wounds. By
comparison, MMP9-deﬁciency combined with absence of either tPA or uPAR resulted in no signiﬁcant effect
on wound healing, indicating that the role of uPA during wound healing is independent of uPAR, when MMP9
is absent. Notably, compensatory upregulation of uPA activity was seen in wounds from MMP9-deﬁcient
mice. Taken together, these studies reveal essential functional dependency between MMP9 and uPA during
gestation and tissue repair.d Molecular Medicine, Faculty
svej 3B, Room 6.4.45, DK-2200
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Normal physiological tissue remodeling during development aswell
as tissue repair after exogenous injury depends on a tightly regulated
balance between activated proteolytic enzymes and their inhibitors,
which in concerted action remodel the extracellular matrix and
basement membranes (Almholt et al., 2008a; Page-McCaw et al.,
2007; Schäfer and Werner, 2008; Toriseva and Kähäri, 2009). During
trophoblast implantation, well-controlled proteolysis enables extracel-
lular degradation and phagocytosis of maternal cells. At least three
classes of proteases, i.e. the serine proteases, the metalloproteinases,
including the matrix metalloproteinases (MMPs), a disintegrin and
metalloproteinases (ADAMs), a disintegrin and metalloproteinase with
thrombospondin type 1 motifs (ADAMTS), and the cysteine proteases
are involved in this process. The expression of the serine protease
urokinase-type plasminogen activator (uPA) (Sappino et al., 1989;
Teesalu et al., 1998), andMMPs, includingMMP1 (i.e.mColA inmice), 2,
9, and 11 (Alexander et al., 1996; Balbin et al., 2001; Cross et al., 1994;
Teesalu et al., 1999) as well as the cysteine proteases Cathepsin B,
Cathepsin L, and placenta-speciﬁc cathepsins (Afonso et al., 1997;Screen et al., 2008; Varanouet al., 2006) in trophoblast giant cells and/or
the decidua suggests that they play important role(s) during implan-
tation and placentation. In contrast, in vivo the serine protease tissue-
type plasminogen activator (tPA) is neither expressed by trophoblast
nor decidual cells at any time during implantation, but is solely found in
the uterine secretory epithelium and in the endothelial cells at later
stages of placenta formation (Sappino et al., 1989). In vitro, tPA is,
however, expressed by parietal endoderm cells derived from mouse
embryos (Marotti et al., 1982).
To determine the importance of single proteases for the accom-
plishment of successful gestation, gene-targeted mice lacking func-
tional genes have been generated. Deleting speciﬁc components of the
plasminogen activation system did not affect the viability and fertility
of homozygous plasminogen (Plg), uPA, tPA, and uPA receptor (uPAR)
knockout animals, and breeding of these mice revealed an expected
Mendelian distribution among their offspring (Bugge et al., 1995a,b;
Carmeliet et al., 1994; Ploplis et al., 1995). With regard to the MMPs,
all of the so far examined MMP null mice, with the exception of
MMP14, are fertile, giving birth to offspring that are born with a
normal Mendelian segregation (for a review see (Page-McCaw et al.,
2007)). Similarly, both Cathepsins B and L alone and in combination
are dispensable during gestation (Felbor et al., 2002). Taken together,
these data suggest that complex interactions between the proteases
exist to ensure that appropriate maternal and fetal connections are
made during both implantation and at later stages of embryonic
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bined with pharmacological inhibition of a distinct class of proteases
indicate that proteolytic activity is crucial for successful implantation
and that there is considerable functional redundancy between
members of the same classes as well as between the various classes
of proteases (Afonso et al., 1997; Solberg et al., 2003).
Cutaneouswound healing, which is a dynamic process dependent
on well-regulated cross-talk between the injured epithelium and
dermis, combines active tissue remodeling with local activation of
various immune functions in order to defeat infection. A number of
different types of cells are involved, including (i) activatedmigrating
keratinocytes that regenerate the cutaneous physical barrier,
(ii) dermal ﬁbroblasts that produce the extracellular scaffold, and
(iii) monocytes that inﬁltrate the wound matrix and produce
cytokines, which stimulate various functions, including immunity,
remodeling, and ﬁnal maturation of the granulation tissue (for
reviews see (Martin, 1997; Schäfer and Werner, 2008; Singer and
Clark, 1999)). The absence of Plg impairs the re-epithelialization that
ultimately does occur (Lund et al., 2006; Rømer et al., 1996), while
healing in uPA and tPA single-deﬁcient mice is signiﬁcantly less
affected (Lund et al., 2006). So far, deﬁciencies of sixMMPs have been
analyzed in wound healing (MMP2, 3, 8, 9, 13, and 14), of which
MMP3, 9, and 13 are expressed in the leading-edge keratinocytes
(Bullard et al., 1999; Frøssing et al., 2010; Gutierrez-Fernandez et al.,
2007; Hartenstein et al., 2006; Kyriakides et al., 2009; Mirastschijski
et al., 2004; Mohan et al., 2002). Separately these three proteases
appear to have modest impact on healing time. Interestingly, wound
healing is severely delayed in transgenic mice (Beare et al., 2003), in
which collagen type 1 is rendered resistant to degradation by
collagenases such as MMP13. Treatment of wild-type mice with the
broad-spectrummetalloproteinase inhibitor, Galardin, which inhibits a
number of individual MMPs, ADAMs, and ADAMTS with different IC50
values (Saghatelian et al., 2004; Uttamchandani et al., 2007), reveals a
severe impairment of healing (Lund et al., 1999). Interestingly, Galardin
treatmentofmicewithdefectivePlg genes results in a complete arrest of
the healing process (Lund et al., 1999, 2006). These ﬁndings suggest an
important functional overlap between Plg and one or several as yet
unidentiﬁed metalloproteinases.
In a ﬁrst attempt to identify the metalloproteinases responsible for
the healing arrest as well as the implantation defect observed in
Galardin-treated Plg-deﬁcient mice, we recently combined deﬁciency
for a single speciﬁc MMP, namely either MMP2, 3, 9, or 13, with Plg-
deﬁciency. Intercrosses of MMP9;Plg double-heterozygous mice
resulted in a non-Mendelian distribution among the F2 offspring
(Hald et al., 2011), whereas an expected segregation was found
among the F2 offspring of MMP2;Plg, MMP3;Plg, and MMP13;Plg
double-heterozygous mice (Frøssing et al., 2010; Juncker-Jensen and
Lund, 2011). Moreover, observation of a cohort of MMP9;Plg double-
deﬁcient mice revealed severe abnormal inﬂammation in the
gastrointestinal tract, eventually leading to obstructive and lethal
inﬂammatory mass lesions in the transverse colon in the double-
deﬁcient mice, whereas no aberrant growth was observed in neither
MMP9 nor Plg single-deﬁcient mice (Hald et al., 2011). These ﬁndings
demonstrate a functional overlap betweenMMP9 and Plg both during
implantation and physiological remodeling of the gastrointestinal
tract, whereas no signiﬁcant additive effect of deﬁciency for both
MMP9 and Plg was observed on bone growth and wound healing
(Hald et al., 2011). In the present study, we aimed at identifying the
Plg activator responsible for the phenotypical deﬁciencies observed in
unchallenged MMP9;Plg double-deﬁcient mice. In order to address
this question, we have generated mice deﬁcient for MMP9 and either
uPA, tPA, or uPAR, which show overlapping expression patterns
compared to MMP9 during gestation (Alexander et al., 1996; Sappino
et al., 1989; Solberg et al., 2003; Teesalu et al., 1998) and in leading-
edge keratinocytes during wound healing (Grøndahl-Hansen et al.,
1988; Lund et al., 1999; Madlener et al., 1998; Rømer et al., 1994).Using these mice, we demonstrate that uPA- and tPA-catalyzed
plasminogen activation combined with MMP9 is equally important
for successful gestation, whereas only uPA-mediated plasminogen
activation together with MMP9 activity are indispensable for normal
skin wound healing and bone growth. These data demonstrate a
hitherto unappreciated critical role for uPA during gestation and
tissue repair in the absence of MMP9.Materials and methods
Mice breeding and treatment
The generation of mice single-deﬁcient for MMP9, uPA, tPA, and
uPAR has previously been described (Bugge et al., 1995b; Carmeliet
et al., 1994; Vu et al., 1998) and these were backcrossed into a FVB/n
background for 10, 19, 20, and 15 generations, respectively.
Alternatively, MMP9- and uPA-deﬁcient mice were backcrossed
into a C57Bl/6J background for at least 35 generations. Mice
heterozygous for MMP9 and either uPA, tPA, or uPAR were crossed
followed by interbreeding of the double-heterozygous offspring to
produce double-deﬁcient mice and littermates of single-deﬁcient as
well as wild-type mice. For genotyping, chromosomal DNA from a 2-
mm piece of the tail tip was isolated essentially as described (Laird
et al., 1991) and used for multiplex PCR. For theMMP9;uPA interbred
mice the following six primers were combined in one tube: MMP9-
wt1, MMP9-wt2, MMP9neo-1p, muPA-8p, muPA-4m, and mPGK-
2m. For the MMP9;uPAR interbred mice the six primers were:
MMP9-wt1, MMP9-wt2, MMP9-ko1, muPAR-1p, muPAR-3m, and
hHPRT-2m. For the MMP9;tPA interbred mice, separate tubes were
set up for MMP9with the three primers MMP9-wt1, MMP9-wt2, and
MMP9-ko1, and for tPA with the three primers mtPA-3m, mtPA-4p,
and mPGK-2m.
The primer MMP9-wt1 (GCA TAC TTG TAC CGC TAT GG) (Perez
et al., 2005), hybridizing to positions 1778–1797 in the mouse MMP9
gene (GenBank: X72794), and MMP9-wt2 (TAA CCG GAG GTG CAA
ACT GG) (Perez et al., 2005), hybridizing to positions 2071–2052,
generate a 294 bp product speciﬁc for the endogenous allele. MMP9-
wt1 combined with either MMP9neo-1p (TCG CCT TCT TGA CGA GTT)
or MMP9-ko1 (GAC CAC CAA GCG AAA CAT) (Perez et al., 2005),
hybridizing within the Neomycin cassette, generate products of
379 bp and ~750 bp that are speciﬁc for the targeted MMP9 allele.
The primer muPA-8p (GGG TCT GGG AAA GCA CTG GAG AG),
hybridizing to positions 7605–7627 in themouse uPA gene (GenBank:
M17922), and muPA-4m (AGA GGA CGG TCA GCA TGG GAA C) (Lund
et al., 2006), hybridizing to positions 8029–8008, generate a 425 bp
product speciﬁc for the endogenous allele. muPA-4m and mPGK-2m
(GCC TTG GGA AAA GCG CCT C) (Lund et al., 2006), hybridizing to
positions 1092–1074 in the mouse phosphoglycerate kinase-1
promoter (GenBank: X15339), generate a ~186 bp product speciﬁc
for the targeted uPA allele. The primer muPAR-1p (ACC TCC ACA AGA
GCA CAC AAG CAC), hybridizing to positions 4568–4591 in the mouse
uPAR gene (GenBank: U12235), and muPAR-3m (TGA CAC TCC TGG
CCG CAG AG), hybridizing to positions 4982–5001, generate a 434 bp
product speciﬁc for the endogenous allele. The primer hHPRT-2m
(GCC CGA GCC CGC ACT G), hybridizing within the inserted HPRT
cassette, and muPAR-1p generate a 191 bp product speciﬁc for the
targeted allele. Genotyping for the tPA alleles was performed as
described in (Lund et al., 2006).
All experimental evaluations, tissue isolations, and microscopic
analyses were performed by investigators unaware of the mouse
genotype. All mice used for the experiments were re-genotyped at the
end of the experiment. Animal care at The Department of Experi-
mental Medicine, University of Copenhagen, Copenhagen, Denmark
was in accordance with the institutional and national guidelines
(permission number 2007/561-1353).
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A cohort of male and female littermate mice was bred and
consisted of the following four groups: wild-type, MMP9 single-
deﬁcient, uPA single-deﬁcient, and MMP9;uPA double-deﬁcient FVB/
n mice. The cohort was followed for 22 weeks, i.e. from weeks 4 to 26
of age, during which time themice were observedmacroscopically for
phenotypical changes at least twice a week and the weight of themice
was recorded once a week. Scanning analysis of 8 mice (2 of each
genotype) at week 26 of age was performed by a MicroCAT II
tomograph CT scanner (Siemens Medical Solutions, Malvern, PA).
Tissue and bone isolation and preparation
At the end of the observation period (i.e. at 26 weeks of age) or in
cases of premature euthanasia due to ethical reasons, the mice were
anesthetized by intraperitoneal administration of 0.1 ml/10 g mouse of
a 1:1 mixture of Dormicum (Midazolam 5mg/ml) and Hypnorm
(Fluanison 5 mg/ml and Fentanyl 0.1 mg/ml). Subsequently, the mice
wereperfusedby intracardial injectionof 10 ml coldphosphate buffered
saline (PBS) followed by 10ml cold 4% paraformaldehyde (PFA) in PBS
before isolation of tissue for standard parafﬁn embedding. The length of
long bones was measured by use of a caliper.
Wound healing
Cohorts of 6–8 week old wild-type, MMP9-deﬁcient, uPA-deﬁcient,
MMP9;uPAdouble-deﬁcient, tPA-deﬁcient,MMP9;tPAdouble-deﬁcient,
uPAR-deﬁcient, and MMP9;uPAR double-deﬁcient mice were anesthe-
tized as described above, and 20mm long full-thickness incisional
skin wounds were made mid-dorsally with a scalpel. The wounds
were neither dressed nor sutured. The wound length and width were
measured every second day by a caliper. The mice were caged
individually until sacriﬁce, at which time they were anesthetized,
followed by perfusion and ﬁxation with PBS and 4% PFA, respectively.
The tissueswere removed forhistological analysis andwoundextracts as
described previously (Frøssing et al., 2010; Lund et al., 1999).
Histological examinations
Hematoxylin and eosin (H&E) staining was performed on 4-μm
thick parafﬁn sections obtained from wild-type, uPA-deﬁcient, and
MMP9-deﬁcient mice. The sections were de-parafﬁnized in xylene
and hydrated through ethanol/water dilutions, followed by staining in
Mayer's hematoxylin (5 min). Sections were then washed in tap
water (5 min), stained with eosin yellow (5 min), rinsed in tap water
(5 min), dehydrated and mounted with pertex.
Immunoperoxidase staining for MMP9 in skin wound lesions was
carried out with 4-μm thick parafﬁn sections obtained fromwild-type,
uPA-deﬁcient, and MMP9-deﬁcient mice. Sections were treated with
proteinase K (5 μg/ml) for 15 min at 37 °C and incubated with a rabbit
polyclonal antibody against murine MMP9 (Ab38898; Abcam,
Cambridge, UK) and detected with EnVisionTM HRP rabbit reagent
(K4003, Dako, Glostrup, Denmark) as described in (Rasch et al., 2010).
Sections were developed with NovaRed chromogen (Vector Labora-
tories, Burlingame, CA) and counterstained with Mayer's hematoxy-
lin, dehydrated, and mounted with pertex.
In vitro transcription and in situ hybridization
Antisense and sense uPA riboprobes were generated from plasmid
pmuPA07 (Kristensen et al., 1991) by incorporation of 35S-labeled
UTP (NEN, Boston, MA) via in vitro transcription using Sp6/T7 RNA
polymerase (Roche, Basel, Switzerland). The DNA templates were
digested with DNase (Promega, Madison, WI). Unincorporated 35S-
labeled UTP and DNA were removed using RNeasy MinElute Cleanupkit (Qiagen, Hilden, Germany). The 35S-radioactivity concentration of
the probes was adjusted by dilution in 10 mM DTT and de-ionized
formamide to 750,000 cpm/μl. Under RNase-free conditions 3-μm
parafﬁn sections were de-parafﬁnized with xylene, hydrated and
washed with PBS (130 mM NaCl, 7 mM NaH2PO4, pH 7.0) and pre-
treated with TEG-buffer (10 mM Tris, 0.5 mM EDTA, pH 9.0) for
10 min at 98 °C under RNase-free conditions, as described in
(Illemann et al., 2009).
Computer-assisted morphometry
Keratinocyte migration was measured in days 7 and 14 skin
wounds by histological analysis of tissue sections immunohisto-
chemically stained for cytokeratin as described (Lund et al., 2006).
Each data point was the mean of two measurements. Image analysis
was performed using the Visiomorph software package (Visiopharm,
Hørsholm, Denmark).
Zymography and Western blotting
Wound tissue specimens containing both the wound rim and
granulation tissue was lysed in 150 mM NaCl, 1% NP-40, 0.5%
deoxycholic acid, 0.1% SDS, 50 mM Tris, pH 8.0. Pools of crude
wound extracts from 3 mice with 7 day old incision were used for the
ﬁbrin/Plg overlay zymograms (16 μl per lane) and the gelatin
substrate zymograms (2.5 μg per lane), as described previously
(Lund et al., 1996), except that the ﬁbrin/Plg overlay zymograms
were incubated for 48 h in the absence or presence of the uPA activity
blocking monoclonal antibody (mU1, 65 μg/ml) (Lund et al., 2008)
and the gelatin substrate zymography was carried out in the absence
or presence of 10 mM EDTA as control for blocking of MMP activity. A
mixture of puriﬁed human pKal (3.6 μg) (Kordia Life Sciences, The
Netherlands), murine uPA (0.1 ng) (Lin et al., 2010), and human tPA
(0.02 ng) (Actilyse, Boehringer Ingelheim, Germany) was included as
control. SDS-PAGE under non-reducing conditions and Western blot
was performed using an in-house polyclonal antibody against mouse
uPA as previously described (Connolly et al., 2010; Lund et al., 2008)
and a β-actin antibody (Abcam, ab6276) according to the manufac-
turer's instructions.
Statistics
Comparisons of the distribution of genotype by gender and the
distribution of genotypes to the expected Mendelian distribution
were done using the χ2-test.
For survival analysis, the distribution of deaths by genotype for
each gender was done using a χ2-test with exact p-values.
The analysis of weight was performed using mixed modeling with
genotype, gender, and age in weeks entered as ﬁxed variables and the
experimental animal as a random effect with weight log transformed.
Model validation was done using conventional methods and by
removing subjects dying in the course of the experiment and
recalculating. Weights of animals removed from the dataset due to
death were not imputed, and an analysis of robustness of the model
was done by removing all animals dying in the course of the
experiment and also by limiting the analysis to up to 23 weeks
(most animals dying did so after 23 weeks) and removing the ﬁrst
time points. Removing all animals dying yielded almost the same
estimates (up to third decimal). Restricting the analysis to 23 weeks
showed a slightly higher estimate of growth. Removing the ﬁrst time
points gave slightly lower estimates but the same pattern and
signiﬁcance levels were seen. Growth rate was estimated as the
mean change in weight per week.
The analysis of bone length was performed using a general linear
model with genotype and gender entered as explanatory variables
and bone length as the dependent variable.
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using a general linear model with genotype as a ﬁxed effect and
stratiﬁed by cohort. The healing time was log transformed. A
comparison between the 3 cohorts was done for wild-type mice.
Kaplan–Meier estimates of the proportion with complete re-
epithelialization as a function of time were plotted. Statistical analysis
of the relative re-epithelialization at days 7 and 14 was performed
using the Kruskall–Wallis test and the Wilcoxon rank sum test
comparing pairs of genotypes. Non-parametric methods were chosen
as the distribution at day 14 was clearly non-normal. No adjustment
for multiple-testing was done.
For all statistical analyses, p-values less than 5% were considered
signiﬁcant. Calculations were done using SAS (v9.1, SAS Institute,
Cary, NC).Results
Gestation is impaired by simultaneous lack of MMP9 and either uPA or tPA
To examine and compare the effect of lack of either uPA or tPA,
combined with MMP9-deﬁciency during gestation, we set out to
generate MMP9;uPA and MMP9;tPA double-deﬁcient mice. Mice
lacking one or more MMP9 and uPA alleles were obtained by
intercrosses of double-heterozygous F1 parents. Analysis of the
weaned F2 offspring revealed a non-Mendelian distribution
(pb0.0001, Table 1). There was a noticeable reduction in the number
of double-deﬁcient offspring and mice lacking MMP9 and one allele
of uPA (MMP9−/−;uPA−/− and MMP9−/−;uPA−/+). This non-
Mendelian inheritance pattern was observed in both genders of the
F2 offspring and the distribution between males and females was not
different (p=0.56, data not shown). These results demonstrate that
concomitant ablation or reduction of MMP9 and uPA affects the
outcome of gestation and postnatal survival as determined by
genotyping of the weaned offspring. Next, to test whether ablation
of tPA together with simultaneous lack of MMP9 is as detrimental for
gestation as observed in mice double-deﬁcient in MMP9 and uPA, the
genotypes of weaned F2 offspring from double-heterozygous MMP9;
tPA F1 parents were analyzed. A signiﬁcant deviation from the normalTable 1
Genetic distribution of F2 offspring after interbreeding of double-heterozygous parents.
FVB/n MMP9;uPA
F2
FVB/n MMP9;tPA
F2
FVB/n MMP9;uPAR
F2
Obs. Exp. Obs. Exp. Obs. Exp.
1. ++/++ 51
(7.13)
44.69
(6.25)
67
(8.48)
49.38
(6.25)
24
(6.65)
22.56
(6.25)
2. −+/++ 103
(14.41)
89.38
(12.50)
104
(13.16)
98.75
(12.50)
56
(15.51)
45.13
(12.50)
3. ++/−+ 85
(11.89)
89.38
(12.50)
125
(15.82)
98.75
(12.50)
40
(11.08)
45.13
(12.50)
4. −+/−+ 212
(29.65)
178.75
(25.00)
216
(27.34)
197.50
(25.00)
111
(30.75)
90.25
(25.00)
5. −−/++ 35
(4.90)
44.69
(6.25)
22
(2.78)
49.38
(6.25)
15
(4.16)
22.56
(6.25)
6. −−/−+ 53
(7.41)
89.38
(12.50)
58
(7.34)
98.75
(12.50)
39
(10.80)
45.13
(12.50)
7. ++/−− 40
(5.59)
44.69
(6.25)
67
(8.48)
49.38
(6.25)
20
(5.54)
22.56
(6.25)
8. −+/−− 117
(16.36)
89.38
(12.50)
113
(14.30)
98.75
(12.50)
44
(12.19)
45.13
(12.50)
9. −−/−− 19
(2.66)
44.69
(6.25)
18
(2.28)
49.38
(6.25)
12
(3.32)
22.56
(6.25)
Total 715 715 790 790 361 361
χ2 test pb0.0001 pb0.0001 p=0.033
The F2 offspring from interbreeding of double-heterozygous F1 breeding pairs (MMP9;
uPA,MMP9;tPA, andMMP9;uPAR) was genotyped at weaning. The numbers in brackets
indicate the incidence percentage.Mendelian ratio (pb0.0001, Table 1) with a marked reduction in the
number of MMP9−/−;tPA−/−, MMP9−/−;tPA−/+, and MMP9−/−;
tPA+/+ offspring was seen.
Gestation is affected by simultaneous lack of MMP9 and uPAR
In order to examine whether the reduction in MMP9;uPA double-
deﬁcient mice among the F2 offspring is partly or completely
dependent on the binding of uPA to its receptor, uPAR, intercrosses
of double-heterozygous MMP9;uPAR F1 parents were carried out. A
non-Mendelian distribution among the offspring was found
(p=0.033, Table 1), with only the number of double-homozygous
MMP9;uPAR-deﬁcient mice markedly reduced.
Survival, weight, and bone growth are affected in unchallenged MMP9;
uPA double-deﬁcient mice
To investigate if the non-Mendelian distribution of the F2 offspring
observed at weaning was also present at birth, offspring from F1
MMP9;uPA double-heterozygous parents were analyzed. At birth this
distribution was also non-Mendelian (p=0.014, Table 2) and not
signiﬁcantly different from the distribution at weaning (p=0.47).
To obtain further insight into the survival and development of
MMP9;uPA double-deﬁcient mice, a prospective cohort consisting of
female and male wild-type, MMP9 single-deﬁcient, uPA single-
deﬁcient, and MMP9;uPA double-deﬁcient mice was established and
observed for 22 weeks (Fig. 1). In general, male mice with a combined
homozygous deﬁciency in MMP9 and uPA appeared runted and
unnursed and had a shorter lifespan (3 out of 13 died) than wild-type
littermates (0/23) (Fig. 1A). The uPA single-deﬁcient male mice also
showed decreased survival (6/13), which was due to occasional
development of jaw or anal abscesses as well as ulcerative rectal
prolapses. All MMP9;uPA double-deﬁcient and uPA single-deﬁcient
female mice survived. Accordingly, the χ2-test revealed that survival
correlated with genotype in male mice (pb0.0001), while no
genotype-dependent association was found among the female mice.
The weight of mice in the cohort was recorded once a week for
22 weeks, starting at the age of 4 weeks. Analyzing weight as a
function of gender, genotype, and age revealed signiﬁcant weight andTable 2
Genetic distribution of F2 offspring after interbreeding of double-heterozygous parents.
FVB/n MMP9;uPA F2
birth
C57BI/6J MMP9;uPA F2
weaning
Obs. Exp. Obs. Exp.
1. ++/++ 29
(8.41)
21.56
(6.25)
48
(6.14)
48.88
(6.25)
2. −+/++ 51
(14.78)
43.13
(12.50)
100
(12.79)
97.75
(12.50)
3. ++/−+ 53
(15.39)
43.13
(12.50)
90
(11.51)
97.75
(12.50)
4. −+/−+ 88
(25.51)
86.25
(25.00)
184
(23.53)
195.50
(25.00)
5. −−/++ 20
(5.80)
21.56
(6.25)
50
(6.39)
48.88
(6.25)
6. −−/−+ 31
(8.99)
43.13
(12.50)
92
(11.79)
97.75
(12.50)
7.++/−− 13
(3.77)
21.56
(6.25)
50
(6.39)
48.88
(6.25)
8.−+/−− 49
(14.20)
43.13
(12.50)
113
(14.45)
97.75
(12.50)
9.−−/−− 11
(3.19)
21.56
(6.25)
55
(7.03)
48.88
(6.25)
Total 345 345 782 782
χ2 test p=0.014 p=0.769
The F2 offspring from interbreeding of double-heterozygous F1 breeding pairs (FVB/n
MMP9;uPA and C57BI/6J MMP9;uPA) was genotyped at birth or at weaning,
respectively. The numbers in brackets indicate the calculated incidence percentage.
Fig. 1. Concomitant MMP9 and uPA gene-deﬁciency exaggerates the effect observed in single-deﬁcient mice on bone growth. (A–B) Cohorts of male and female mice are presented in
the left and right panel, respectively. (A) Survival data are shown for a cohort of wild-type, MMP9-deﬁcient, uPA-deﬁcient, and MMP9;uPA double-deﬁcient mice. The total number
of mice (n) in each group is indicated together with the number of mice that died during the 22 week observation period in brackets. (B) Plot of weight versus age of the mice in the
cohorts in A. (C) X-ray pictures of 26 weeks old male wild-type, MMP9-deﬁcient, uPA-deﬁcient, and MMP9;uPA double-deﬁcient mice. (D) The mean bone length of tibia, isolated
fromwild-type (n=14♂; 13♀), MMP9-deﬁcient (n=14♂; 10♀), uPA-deﬁcient (n=7♂; 12♀), and MMP9;uPA double-deﬁcient (n=11♂; 4♀) mice at age 26 weeks is presented
as horizontal lines in the scatter plots.
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4 weeks, males weighed 16.9% (95% CI: 14.0 to 19.8%) more than
females. The weight of wild-type and uPA-deﬁcient mice was larger
than that of MMP9 single-deﬁcient and MMP9;uPA double-deﬁcient
littermates at 4 weeks and at later time points. As an example, at
16 weeks of age, the weight of uPA-deﬁcient mice was 1.4% (95% CI:
−2.0 to 4.8%) higher than that of wild-type mice, whereas the mean
weight was reduced by 6.6% (95% CI:−10.0 to−3.6%) and 8.8% (95%
CI: −12.3 to −5.3%) for MMP9 single-deﬁcient and MMP9;uPA
double-deﬁcientmice, respectively. The results of themixedmodeling
analysis could not demonstrate a signiﬁcant interaction between
gender and genotype (p=0.62), showing that the relative weight
differences between genotypes were independent of gender. A
signiﬁcant interaction between age and gender was found
(p=0.003), i.e. females had a higher growth rate than males. The
analysis also demonstrated that MMP9;uPA double-deﬁcient mice
had a slightly but signiﬁcantly higher growth rate (p=0.005) than
mice of the other three genotypes, although the weight of the MMP9;uPA double-deﬁcient mice never reached the level of the MMP9
single-deﬁcient mice.
By observations of the size of the mice in the cohort, both MMP9-
deﬁcient and MMP9;uPA double-deﬁcient mice appeared smaller
than wild-type and uPA-deﬁcient littermates at the age of 4 and
26 weeks (data not shown).
We next measured the length of tibiae isolated from the mice at
26 weeks of age (see X-ray pictures of the hind legs of the mice in
Fig. 1C). A test for interaction between gender and genotype was not
signiﬁcant (p=0.23), suggesting a similar effect of genotype formales
and females. The results of the linear model adjusted for gender
demonstrated a signiﬁcant difference for genotypes (pb0.0001). The
MMP9-deﬁcient mice had signiﬁcantly shorter bones as compared to
wild-type mice (−0.94 mm, 95% CI:−1.19 to−0.69, pb0.0001) and
uPA-deﬁcient mice (−1.11 mm, 95% CI:−1.38 to−0.83, pb0.0001),
while no difference in bone length was observed between uPA-
deﬁcient mice and wild-type littermates (p=0.22). Interestingly, a
signiﬁcant decrease in bone length was observed in MMP9;uPA
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(−0.31 mm, 95% CI:−0.60 to−0.02, p=0.038) (Fig. 1D), suggesting
that there is an additive effect on bone growth upon ablation of both
uPA and MMP9.
Wound healing is severely impaired in MMP9;uPA but not in MMP9;tPA
or MMP9;uPAR double-deﬁcient mice
Based on the similar expression patterns of MMP9 and uPA in
leading-edge keratinocytes during skin wound healing (Grøndahl-
Hansen et al., 1988; Lund et al., 1999; Madlener et al., 1998), we
examined the effect of deﬁciency in either MMP9, uPA, or both pro-
teases on wound healing. Standardized 20 mm long, full-thickness,
incisional skin wounds were generated in a cohort of mice consisting
of wild-type mice, MMP9-deﬁcient mice, uPA-deﬁcient mice, and
MMP9;uPA double-deﬁcient mice. The wounds were grossly exa-
mined by visual inspection and the wound lengths measured every
second day. Following surgery, the wounds were found to be spindle-
shaped with a well-separated incision interface and exposed
underlying muscle fascia. With the notable exception of the MMP9;
uPA double-deﬁcient mice, in which the wound edges became
increasingly elevated 2–3 days post-wounding and until healing
(Fig. 2A), the wounds in all other groups were covered by a
dehydrated wound crust by the second day post-wounding, which
was gradually lost during the healing process. Healing was deﬁned as
a complete loss of the wound scab and closure of the incision interface
with restoration of the covering epidermis.
The mean times to complete healing for mice with single
deﬁciencies in either MMP9 or uPA were delayed to 19.5 and
21.8 days, respectively, which for the uPA-deﬁcient mice in particular
is signiﬁcantly longer than the healing time of 16.3 days in wild-type
mice (pb0.0001, Figs. 2B–D, left panel). In mice with simultaneous
lack of MMP9 and uPA, the mean healing time increased to 28.6 days,
a signiﬁcant delay in skin wound healing compared to the wild-type
mice (pb0.0001) and also to uPA single-deﬁcient (p=0.0005) and
MMP9 single-deﬁcient (pb0.0001) mice (Fig. 2D). Hence, combined
ablation of the genes for MMP9 and uPA results in an augmented
impairment of the wound healing process compared to littermate
mice with single-deﬁciencies.
In a number of physiological tissue remodeling processes, the two
plasminogen activators uPA and tPA have been demonstrated to
possess overlapping roles (Bugge et al., 1996; Carmeliet et al., 1994;
Leonardsson et al., 1995; Lund et al., 2006), and we therefore
investigated whether tPA played a role with regard to cutaneous
wound healing in the absence of MMP9. Though a marginal effect was
seen on the average wound healing time upon combined ablation of
MMP9 and tPA as compared to wild-type and tPA single-deﬁcient
mice, no difference was seen when compared to MMP9 single-
deﬁcient mice (Figs. 2B–D, middle panel). This suggests that tPA-
catalyzed plasminogen activation is not critical for wound healing,
whether MMP9 is present or absent.
As the binding of uPA to uPAR focuses plasminogen activation to
the cell surface (Ellis et al., 1991), we decided to investigate whether
the observed effect caused by combined lack of MMP9 and uPA in skin
wound healing is dependent on uPAR. As demonstrated in Figs. 2B and
C (right panel), the absence of both MMP9 and uPAR neither delayed
the healing process of the wounds nor did it affect the wound length
(p=0.78), suggesting that the effect of uPA on wound healing, in
combination with MMP9, is independent of (its binding to) uPAR.
Results of the three independently performed wound healing
experiments can be directly compared and are highly reproducible, as
an analysis of healing times for wild-type mice demonstrated no
signiﬁcant differences between the groups (p=0.73). Collectively,
our wound healing experiments suggest that simultaneous absence of
both MMP9 and uPA results in an additive delay in wound healing.
Hence, our results propose that there is a functional overlap betweenMMP9 and uPA in this tissue remodeling process, in such a speciﬁc
way that their capability to substitute each other's functions is
independent of tPA-catalyzed plasminogen activation and apparently
also of the binding of uPA to uPAR.
Histological differences between skin wounds in MMP9;uPA double-
deﬁcient mice compared to MMP9 and uPA single-deﬁcient and wild-
type mice
To obtain further insight into the physiological processes occurring
during wound healing in the absence of the proteases, we ﬁrst
analyzed H&E-stained wound sections from wild-type, MMP9-
deﬁcient, uPA-deﬁcient, and MMP9;uPA double-deﬁcient mice at
days 7 and 14 post-wounding. At day 7 post-wounding, the leading-
edges of skin wounds in wild-type and MMP9-deﬁcient mice had
progressed far underneath the wound scab with concerted formation
of granulation tissue, whereas wounds in uPA-deﬁcient mice and
MMP9;uPA double-deﬁcient mice revealed impaired keratinocyte
migration and a typical blunt end of the leading-edge keratinocytes
(Figs. 3e and f compared to g and h). In MMP9;uPA double-deﬁcient
mice, an eosin-positive matrix accumulated underneath and in front
of the leading-edge keratinocytes (Fig. 3h). This was even more
evident at day 14, where the majority of wild-type (9/10) and MMP9-
deﬁcient mice (7/10) had an intact epidermis (Figs. 3m and n), in
contrast to uPA-deﬁcient mice where only a minority (3/13) and none
of the wounds from MMP9;uPA double-deﬁcient mice (0/8) were
covered by an intact epidermis (Figs. 3o and p). The wound bed was
furthermore found to be elevated compared to the adjacent non-
injured skin in most MMP9;uPA double-deﬁcient mouse wounds. The
leading-edge keratinocytes were irregular in shape, with several
apparently aborted invasive fronts, and with accumulation of
amorphous material in front of and/or underneath the newly formed
epidermis (Fig. 3p).
To determine the impact of deﬁciency in MMP9 and/or uPA on re-
epithelialization, we next measured the relative wound closure
by morphometric analyses at days 7 and 14 after incisional skin
wounding. We calculated the percentage fraction of the wound width
covered by keratinocytes from both sides of the wound (Lund et al.,
2006). Seven days after wounding no difference in re-epithelialization
between MMP9-deﬁcient mice (38.9%) and wild-type mice (45.6%)
was seen, whereas mice deﬁcient for uPA alone (26.6%) or in
combination with MMP9 (30.6%) had signiﬁcantly (pb0.001) less
covering of epidermis than both wild-type mice and MMP9-deﬁcient
mice (Fig. 3, lower left panel). No signiﬁcant difference was, however,
observed between uPA-deﬁcient and MMP9;uPA double-deﬁcient
mice at days 7 or 14 post-wounding (Fig. 3, lower panel). In wild-type
and MMP9-deﬁcient mice all the wounds were almost completely re-
epithelialized at day 14.
Compensatory upregulation of uPA activity in MMP9-deﬁcient mice
during skin wound healing
The additive effect between uPA and MMP9 during wound healing
prompted a further examination of the expression and activity of
these two enzymes in response to the absence of the other. In both
wild-type and MMP9-deﬁcient mice, we observed uPA mRNA at the
edge of the keratinocyte tongue using in situ hybridization (Fig. 4A, a
and b, respectively), whereas no speciﬁc signal as expected was
detected in wounds from uPA-deﬁcient mice (data not shown). The
uPA mRNA was detectable in the invading keratinocytes as well as
beneath the wound crust. MMP9 protein was located in the same area
of the epidermal tongue (Fig. 4A, c). No MMP9 immunoreactivity was
detected in wounds obtained from MMP9-deﬁcient mice (data not
shown).We observed no obvious differences in uPAmRNA andMMP9
immunoreactivity in the leading-edge keratinocytes in wild-type
mice as compared to MMP9-deﬁcient mice and uPA-deﬁcient mice,
Fig. 2. Different healing kinetics of full-thickness skin wounds in 3 cohorts of protease-deﬁcient mice. (A–D) Wound healing in wild-type, MMP9-deﬁcient, uPA-deﬁcient, and MMP9;uPA
double-deﬁcientmice (left column), inwild-type,MMP9-deﬁcient, tPA-deﬁcient, andMMP9;tPAdouble-deﬁcientmice (middle column), and inwild-type,MMP9-deﬁcient, uPAR-deﬁcient, and
MMP9;uPARdouble-deﬁcientmice (right column)arepresented. (A)Representativeexamplesofwound repairprogression(days7, 14, and21) in the threedifferent cohorts. (B)Thepercentage
of healed wounds in mice plotted versus time after wound incision. A signiﬁcant delay is observed in MMP9;uPA double-deﬁcient mice and a modest delay in both groups of mice with single
deﬁciencies is seen, as compared to wild-type mice. (C) The average wound length is plotted as a function of time after incision. The wound length of MMP9;uPA double-deﬁcient mice was
signiﬁcantly increased compared to both wild-type and MMP9 or uPA single-deﬁcient mice. The average wound length of wild-type, tPA-deﬁcient, and uPAR-deﬁcient mice was in contrast
indistinguishable during re-epithelialization. The symbol and number of mice are shown in panels B and C for each cohort. (D) Statistical analysis of each cohort.
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absence of uPA was, however, associated with intense expression of
MMP9 in a small group of large cells, considered as part of thesubcutaneous muscle located towards the granulation tissue and in
multi-nucleated cells located within the granulation tissue (results
not shown).
Fig. 3. Histological analysis of wounds in wild-type, MMP9-deﬁcient, uPA-deﬁcient, MMP9;uPA double-deﬁcient mice at days 7 and 14 after incision. Upper panels: H&E-stained
sections of wounds isolated from the indicated mice at day 7 and day 14 post-wounding. Images show representative examples of normal appearing non-injured skin with dermis
(D), wound site with newly formed epidermis (E), provisional matrix (*), and the granulation tissue (GT) at low magniﬁcation (a–d and i–l) with inserted frames showing the edge
of the keratinocyte (K) tongue presented in high magniﬁcation (e–h and m–p). Arrow heads indicate the wound edge (a, b, c, d), and arrows mark the keratinocytes (e–h and m–p).
On day 14, all wild-type mice possessed a fully closed wound in contrast to some of the uPA-deﬁcient and MMP9-deﬁcient mice and all double-deﬁcient mice. Note the wound edge
of the double-deﬁcient mice, showing epidermal sprouts into granulation tissue (p, arrows). Bars: ~280 μm (a–d and i–l), ~35 μm (e–h and m–o), and ~140 μm (p). Lower panels:
Morphometric analysis of keratinocyte re-epithelialization in wounds. Scatter plot of the relative re-epithelialization of keratinocytes at day 7 post-wounding (left panel: 12 wild-
type mice, 8 MMP9-deﬁcient, 11 uPA-deﬁcient, and 7 MMP9;uPA double-deﬁcient mice) and at day 14 post-wounding (right panel: 10 wild-type mice, 10 MMP9-deﬁcient, 13 uPA-
deﬁcient, and 8 MMP9;uPA double-deﬁcient mice). The relative migration was determined as the migration distance from the wound edge to the front of the leading-edge
keratinocytes, divided by the distance between the two wound edges.
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upregulation of other proteases may account for the modest
phenotypes observed in single protease-deﬁcient mice (Hartenstein
et al., 2006; Lambert et al., 2003; Lund et al., 2006; Page-McCaw et al.,
2007; Rudolph-Owen et al., 1997). We therefore tested for changes in
the ﬁbrinolytic activity by ﬁbrin overlay zymography of pooledwound
extracts prepared from 3 wild-type, 3 MMP9-deﬁcient, 3 uPA-deﬁcient, and 3 MMP9;uPA double-deﬁcient mice 7 days post-
wounding (Fig. 4B). After standard development of the zymograms,
a strong ﬁbrinolytic activity, corresponding to uPA was found in
extracts fromMMP9-deﬁcient mice, that could be speciﬁcally blocked
by a uPA activity neutralizing monoclonal antibody (mU1) (Lund
et al., 2008). In contrast, virtually no uPA activity was detectable in
wild-type wounds with this development time. Additional
Fig. 4. Gene-speciﬁc compensatory upregulation of uPA in MMP9-deﬁcient mice during
skin wound healing. (A) In situ hybridization of tissue sections from 7 day old skin
wounds for uPA mRNA in wild-type (a) and MMP9-deﬁcient mice (b); immunohis-
tochemical staining for MMP9 on sections of wounds from wild-type (c) and uPA-
deﬁcient mice (d). Distinct expression of uPA mRNA is seen in leading-edge
keratinocytes (K) in wild-type (a, arrows) and MMP9-deﬁcient mice (b, arrows).
Similarly, expression of MMP9 immunoreactivity was observed in wild-type and uPA-
deﬁcient mice in leading-edge keratinocytes (c and d, respectively, arrows). Bars:
~70 μm (a–b) and ~35 μm (c–d). (B) Fibrin overlay zymography of pooled wound
extracts prepared from 3 mice with 7 day old wounds and as control a mixture of
puriﬁed human pKal, murine uPA, and human tPA. In the absence (upper) or presence
of the monoclonal antibody mU1 (65 μg/ml), blocking the function of mouse uPA
(lower). (C) Gelatin substrate zymography of pooled wound extracts from 3 mice
prepared from 7 day old wounds were analyzed in the absence (upper) or presence of
10 mM EDTA (lower) to block MMP activity. (D) Western blot of wound extracts
prepared from 7 day old wounds obtained from 3 uPA-deﬁcient, 3 MMP9-deﬁcient, and
3wild-typemice were analyzed under non-reducing conditions. Similar amount of pro-
uPA/uPA as indicated by the arrow was seen in wild-type and MMP9-deﬁcient mice.
Loading control of the wound lysates by use of β-actin is presented in the lower panel.
The position of the molecular weight marker (kDa) is indicated at the right.
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pendent animals and subjected to different development times,
conﬁrmed increased uPA activity in 3/3 MMP9-deﬁcient mice relativeto wild-type mice (data not shown). The amount of pro-uPA/uPA was
found to be similar in wound lysates from MMP9-deﬁcient and wild-
type mice (Fig. 4D). Collectively, these data suggest a compensatory
upregulation of uPA activity in MMP9-deﬁcient mice. Enzymatic
activity corresponding to tPA was detectable in extracts from uPA-
deﬁcient mice. The wound extracts from mice of all genotypes
contained a substantial ﬁbrinolytic activity corresponding to pKal
(Fig. 4B). No other ﬁbrinolytic activity was observed. Similarly, we
tested for gelatinolytic activities of the wound extracts by gelatin
substrate zymography. No apparent upregulation of gelatinolytic
activities was observed in extracts from any of the single- or double-
deﬁcient mice compared to wild-type mice (Fig. 4C). Notably, no
upregulation of MMP2 activity was observed in mice deﬁcient for
MMP9, parallel to the absence of an upregulation of MMP9 or MMP2
in uPA-deﬁcient mice. These data demonstrate that deﬁciency for a
particular protease can result in a speciﬁc upregulation of the
proteolytic activity of a member of a different class of proteases, but
it is not necessarily reciprocally coupled.
Discussion
It is well-established that cell migration and invasion in normal
physiological tissue remodeling depend on a ﬁnely tuned balance
between activated proteases and their speciﬁc inhibitors (Almholt et al.,
2008b; Page-McCaw et al., 2007). Functional redundancy between
different classes of proteases, such as the serine proteases of the
plasminogen activation system and the proteases belonging to the
family of MMPs, has been demonstrated in several settings of
physiological tissue remodeling as well as in various models of tissue
regeneration following damage, including incisional wound healing
(Almholt et al., 2007; Danø et al., 2005). However, themolecular details
underlying such partial or complete functional overlap are not well
understood. In this studywe provide evidence for amolecular interplay
between two classes of proteases, i.e. the MMPs and the plasminogen
activation system, as well as for a compensatory upregulation of uPA
activity in the absence of MMP9. We also provide evidence for hitherto
unappreciated critical roles for uPA, tPA, and uPAR during gestation in
the absence of MMP9.
Based on their histological expression patterns, MMP9, uPA, and
uPAR were individually claimed to be critical for trophoblast
implantation and placentation (Alexander et al., 1996; Sappino
et al., 1989; Solberg et al., 2003; Teesalu et al., 1998). However, an
expected Mendelian distribution among the offspring was originally
reported after breeding of MMP9, uPA, uPAR, or Plg single-deﬁcient
mice (Bugge et al., 1995a,b; Carmeliet et al., 1994; Ploplis et al., 1995;
Vu et al., 1998). In the present study, we have conﬁrmed the expected
Mendelian distribution of uPA-deﬁcient, tPA-deﬁcient, and uPAR-
deﬁcient mice among the offspring of double-heterozygous breeding
pairs, whereas the number of MMP9-deﬁcient mice was reduced
among the offspring of all three breeding pairs (see Table 1). This
observation suggests that MMP9-activity is less dispensable and not
fully compensated for during gestation compared to lack of uPA, tPA,
and uPAR. It should be emphasized that the effect of deﬁciency for
uPA, tPA, or uPAR is only observed with superimposed MMP9-
deﬁciency, which results in a signiﬁcant decrease in the expected
number of offspring. We found no evidence of a gene dosage effect for
MMP9, as the number of offspring lacking one MMP9 allele was,
regardless of the lack of other genes, not inﬂuenced. We did though
observe a gene dosage effect for uPA and tPA, affecting the number of
offspring lacking one allele of these genes, although these effects
could only be seen in combination with the loss of two MMP9 alleles.
Hence, loss of one uPA or tPA allele in combination with the loss of
two MMP9 alleles is seemingly more severe than the opposite
combination of null alleles. Importantly, the genes analyzed for
Mendelian inheritance are located on different mouse chromosomes
(Chr), excluding any interpretation problems due to effects of
65I.K. Lund et al. / Developmental Biology 358 (2011) 56–67genomic proximity: MMP9 (Chr 2) vs. uPA (Chr 14), tPA (Chr 8), or
uPAR (Chr 7). Thus, the observed non-Mendelian distributions seem
indeed to be caused by insufﬁcient proteolysis during gestation and
emphasizes the pivotal role(s) of these proteases in this process.
The fact that the mothers of the offspring are double-heterozygous
and thus proﬁcient with respect to both genes of interest sub-
stantiates that a critical threshold of focal protease activity derived
from the conceptum is crucial for successful accomplishment of
implantation, placentation, and embryogenesis during gestation. The
molecular mechanisms underlying this still remain to be elucidated in
detail. It is tempting to speculate that the complex lineage
differentiation of the trophoblast giant cells is perturbed by changes
in the microenvironment, eventually leading to premature death and
regression of the conceptum (Hu and Cross, 2010). Unfortunately, this
is not a trivial task to analyze experimentally, because it is not an all or
none effect, since viable double-deﬁcient mice eventually are born
and survived into adulthood. This indicates that the requirement for
MMP9 and uPA or tPA activities must be compensated for by yet
unidentiﬁed protease(s). However, preliminary analyses of uteri
isolated from pregnant MMP9;uPA double-heterozygous mice at day
7.5 to day 15.5 post coitum revealed an increasing number of
regression sites as early as day 8.5 compared to wild-type littermate
parents (L.R. Lund, unpublished data). This may suggest that a critical
spatio-temporal level of proteolytic activity is required throughout
gestation, and that this level is not always fulﬁlled due to insufﬁcient
compensation. It remains to be elucidated if pKal has a similar
relationship as uPA and tPA with MMP9 during gestation. It could be
speculated that ubiquitous occurrence of the liver synthesized pKal
may provide a different spatial distribution compared to uPA and tPA,
both of which are expressed by cells in the local microenvironment.
It should be stressed that the effect on gestation by simultaneous
lack of MMP9 and uPA is dependent on the genetic background of the
mice. An expected Mendelian distribution is observed in the C57Bl/6J
background (Table 2). Strain-dependent effects on a number of
physiological and pathological events have been reported previously,
including susceptibility to inﬂammation, tumor initiation, and
metastasis (Hoover-Plow et al., 2008; Martin et al., 2008; Quigley
et al., 2009). Future experiments are required to identify the genetic
explanation for these ﬁndings, but one possibility is different
expression levels of modiﬁer genes in the various strains.
An unexpected ﬁnding in this study is the difference in weight
between wild-type mice and MMP9-deﬁcient mice throughout the
observation period. Importantly, signiﬁcant and additive effects on
gestation, gender-dependent weight, bone growth, and wound mean
healing time were observed in MMP9;uPA double-deﬁcient mice,
while no overt exaggeration of the unchallenged phenotypes already
manifested in the single-deﬁcient mice was observed in MMP9;uPA
double-deﬁcientmicewith respect to overall survival and ﬁbrin(ogen)
accumulation in liver (data not shown). These results strongly suggest
that compensatory mechanisms can partially alleviate the effects of
the induced stress and that a functional overlap among proteases is
more widespread during development than generally accepted.
Furthermore, our results propose that when the critical rate-limiting
events during gestation and early postnatal development are success-
fully accomplished, combinedMMP9 and uPA activities do not seem to
be required for maintenance of general cellular homeostasis, except
during growth of the long bones. This is apparently not the case in
unchallenged MMP9;Plg double-deﬁcient mice, which develop lethal
obstructive inﬂammatory lesions in the colon (Hald et al., 2011).
Macroscopically, we do not observe similar lesions in MMP9;uPA
double-deﬁcient mice, suggesting that this phenotype requires
complete abolition of all plasmin activity in order to progress. Hence,
uPA and tPA are seemingly not the sole physiologically relevant
plasminogen activators, making the presence of additional plasmin-
ogen activators plausible in the gastrointestinal tract, as already
described formammary gland involution (Selvarajan et al., 2001), skinwound healing (Lund et al., 2006), and regeneration of the bone
marrow after myeloid suppression (Heissig et al., 2007).
Notably, the delay in wound healing time of MMP9;uPA double-
deﬁcient mice compared to wild-type mice was less pronounced than
the delay observed in both Plg single-deﬁcient andMMP9;Plg double-
deﬁcient mice. Mice of the two latter genotypes display similar wound
healing kinetics, demonstrating that there is no synergistic effect of
MMP9 and Plg deﬁciency in this remodeling process (Hald et al., 2011;
Rømer et al., 1996). The difference in healing kinetics may be
attributed to the presence of other physiological plasminogen
activators, such as pKal, which we have previously demonstrated to
have a rate-limiting effect during wound healing in uPA;tPA double-
deﬁcient mice (Lund et al., 2006). In contrast, the concomitant activity
of pKal or another as yet unidentiﬁed plasminogen activator does not
seem to be required during gestation, since the gestational phenotype
of both MMP9;uPA and MMP9;tPA double-deﬁcient mice (Table 1) is
similar to that of MMP9;Plg double-deﬁcient mice (Hald et al., 2011).
Our ﬁnding that the uPA-mediated effect on wound healing seems
to be completely independent of uPAR is intriguing. Speciﬁcally, it
raises a number of questions for the role of uPAR in skin biology. In
vitro binding of uPA to uPAR increases cell-surface plasminogen
activation (Ellis et al., 1991; Stephens et al., 1989) and a number of
gain- and loss-of-function studies have provided compelling evidence
for a critical role of uPA and uPAR during cancer progression (for a
review see (Danø et al., 2005)) as well as for their potential as targets
in pharmacological treatment of cancer (Rømer et al., 2004).
Transgenic mice with a K5 promotor-controlled overexpression of
either uPA or uPAR in the basal keratinocytes have no overt skin
phenotype, whereas concomitant overexpression of both transgenes
results in a plasminogen-dependent abnormal skin phenotype, in-
cluding extensive alopecia, epidermal thickening, and sub-epidermal
blisters (Bolon et al., 2004; Zhou et al., 2000). Interestingly, the
phenotype induced in the teeth by overexpression of uPA is
independent of concomitant overexpression of uPAR. It can thus be
speculated that there are both uPAR-dependent as well as uPAR-
independent effects of uPA during tissue remodeling of the skin,
depending on the nature of the event. These ﬁndings support the
notion that deregulated expression of uPA can be highly detrimental
for a tissue or an organ and emphasize the importance of
understanding in detail the molecular control mechanisms involved,
including identiﬁcation of uPA substrate(s) under both uPAR-
dependent as well as uPAR-independent actions of uPA. In this
context, an interesting ﬁnding is the additive effect of simultaneous
ablation of MMP9 and uPA on long bone length (Figs. 1C and D),
whereas no additive effect was observed on bone length in MMP9;Plg
double-deﬁcient mice (Hald et al., 2011). This ﬁnding indicates the
presence of Plg-independent effect(s) of uPA in distinct tissues.
Identiﬁcation of uPA substrates other than Plg is essential and will be
the focus of future experiments, as additional substrates implicate a
more versatile system than hitherto expected. An equally important
future task is identiﬁcation of common substrates for MMP9 and
plasmin in vivo. A number of substrates have been identiﬁed in vitro
(Cauwe et al., 2007), but attempts to verify the physiological
relevance of these substrates in vivo are sparse. One example is
identiﬁcation of ﬁbrin as a substrate for MMP9 during experimental
nephritis (Lelongt et al., 2001).
It is well-established that uPA and tPA as well as different MMPs
can substitute for each other in a number of physiological processes,
including ovulation (Leonardsson et al., 1995), wound healing (Bugge
et al., 1996; Lund et al., 2006), and involution of the postpartum
uterus (Rudolph-Owen et al., 1997). During wound healing, we ﬁnd
an upregulation of tPA activity in uPA-deﬁcient mice, which may
explain the subtle wound healing phenotype in tPA-deﬁcient mice
reported herein and previously (Lund et al., 2006). Importantly, in this
study we also demonstrate a compensatory upregulation of activity
between different classes of proteases during tissue repair, as we ﬁnd
66 I.K. Lund et al. / Developmental Biology 358 (2011) 56–67markedly increased uPA activity inMMP9-deﬁcientmousewounds by
ﬁbrin overlay zymography, possibly accounting for the delay in
wound healing observed in MMP9;uPA double-deﬁcient as compared
to the MMP9 single-deﬁcient mice. The molecular mechanism
underlying this cross-talk within and between different classes of
proteases remains unknown. As judged from the in situ hybridiza-
tions, we found no obvious difference in the uPA mRNA expression in
wounds from wild-type and MMP9-deﬁcient mice (Fig. 4A). This is in
agreement with Western blot analysis, which under non-reduced
conditions revealed no striking difference in the amount of uPA
protein between wild-type and MMP9-deﬁcient wound extracts. The
augmented uPA activity observed in the absence of MMP9 (Fig. 4B)
may thus be attributed to facilitated and/or enhanced pro-uPA
activation in the MMP9-deﬁcient mice. One possible explanation
could be that excessive accumulation of MMP9 substrates leads to an
environment, which favors other compensatory proteolytic cascades,
including enzymes capable of pro-uPA activation. Interestingly,
increased levels of both murine uPA mRNA and protein have been
found in xenografted tumors from mice treated with the broad-
spectrum inhibitor Batimastat, blocking MMP activity (Holst-Hansen
et al., 2001). One tool for addressing this question is murine
monoclonal antibodies speciﬁcally blocking the function of the target
molecule, e.g. MMP9 or uPA. Treatment of tPA-deﬁcient mice with
such neutralizing antibodies directed against either mouse uPA or
mouse uPAR have been demonstrated to result in delayed wound
healing and/or increased ﬁbrin accumulation, and thus in phenotypes
mimicking those observed in uPA;tPA and uPAR;tPA double-deﬁcient
mice, respectively (Jögi et al., 2007, 2010; Lund et al., 2008).
Conclusion
We have demonstrated pivotal roles for MMP9 together with uPA
or tPA during gestation. Strikingly, concomitant lack of MMP9 and
uPA activities is rate-limiting during skin wound healing, and
seemingly independent on uPAR. An additive effect of MMP9 and
uPA was additionally seen on bone length. Thus, combined deﬁciency
in two distinct proteases enables the identiﬁcation of unrecognized
functions of certain proteases in speciﬁc biological processes.
Furthermore, the herein demonstrated functional overlap includes
both overlapping roles between MMP9 and uPA as well as
compensatory upregulation in activity of the latter protease in the
absence of the former. This emphasizes the importance of future
studies to include mice with two or more deﬁciencies, preferentially
combined with gene-targeted conditional knockout mice as well as
time- and event-speciﬁc protease abolishment, e.g. by treatment with
protease speciﬁc inhibitors, in order to unmask crucial molecular
interactions that otherwise could be easily overlooked. It should be
stressed that such analyses should additionally include extracellular
matrix proteases belonging to families other than serine proteases
and metalloproteinases, e.g. members of the cysteine and aspartate
families.
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